Partnering Strategy

The SciFluor pipeline contains novel and differentiated small molecule compounds in a wide range of disease and therapeutic categories including ophthalmic disease, central nervous system disorders and fibrosis. 13 U.S Patents have been issued covering our promising candidates that have advanced into various stages of development. The company’s business strategy focuses on establishing collaborative partnerships to drive new chemical entities through development and commercialization to address unmet commercial and clinical needs.

Scott Edwards, Ph.D. |

SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >